Strohl, William R. http://orcid.org/0000-0002-8271-6875
Ku, Zhiqiang
An, Zhiqiang
Carroll, Stephen F.
Keyt, Bruce A.
Strohl, Lila M.
Funding for this research was provided by:
Welch Foundation (AU-0042-20030616)
CPRIT (RP150551, RP190561)
Article History
Accepted: 21 March 2022
First Online: 27 April 2022
Declarations
:
: This work was supported in part by a Welch Foundation grant AU-0042-20030616 and Cancer Prevention and Research Institute of Texas (CPRIT) Grants RP150551 and RP190561 (ZA).
: The University of Texas System has filed a patent on the SARS-CoV-2 antibodies and the reverse genetic system and reporter SARS-CoV-2. The University of Texas System and IGM Biosciences Inc. have filed a joint patent on the SARS-CoV-2 IgM antibodies. Z.A. and Z.K. are employed by The University of Texas System. The antibody, IGM-6268 is under development by IGM Biosciences Inc. for prophylactic and therapeutic treatment of COVID-19. B.A.K. and S.F.C. are employees of IGM Biosciences, Inc. W.R.S. is a member of the Board of Directors, IGM Biosciences, Inc., and is a member of the Scientific Advisory Board for Immunome, two companies mentioned in this paper. Other authors declare no competing interests.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable; all codes mentioned herein are public.
: All authors contributed to concepts used to build the manuscript, data analysis, writing, and editing the manuscript. LMS and WRS carried out structural analyses from public databases and made all of the figures.